🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating worldwide, with data suggesting in excess of 82 million new cases each year. Particularly high rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This approval represents a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Results and Worldwide Availability

As per results published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an equal footing with the current standard treatment, which combines an injection and a pill. The study enrolled nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Doctors treating patients have voiced hope. Having a one-pill regimen like this is described as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the infection for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.